In a video interview with CURE, Dr. Elizabeth K. Lee explained that how a treatment affects daily life matters as much as how well it works.
|Articles|May 12, 2015
Dr. Shore Provides an Overview of Biomarkers in Prostate Cancer
Author(s)Neal D. Shore, MD, FACS
Neal D. Shore, MD, FACS, medical director, Carolina Urologic Research Center, provides an overview of biomarkers in prostate cancer.
Advertisement
Neal D. Shore, MD, FACS, medical director, Carolina Urologic Research Center, provides an overview of biomarkers in prostate cancer.
“The field of biomarkers in prostate cancer is exploding exponentially, and it has been for some time now,” Shore says. “The challenge is that most of the biomarkers that are commercially available are not reimbursed and, some might argue, are truly not yet ready for primetime.”
Advertisement
Related to this article
Dr. Neel Chudgar of Montefiore Einstein answers the most searched questions about lung cancer surgery, including risks, recovery and recurrence.
Rinatabart sesutecan shrank tumors in 45.9% of patients with platinum-resistant ovarian cancer in a phase 2 study, with responses lasting a median of 12.1 months.
Prostate cancer grows slowly, and while 50% of men on active surveillance eventually need treatment, waiting can mean years without side effects.
Bern Paul uses close to 10 products from different manufacturers to manage his urostomy after bladder cancer. He explains why Medicare bidding concerns him.
A leukemia survivor recalls how bonding with other patients helped his hospital stays go by faster and became a key part of his emotional healing.
Advertisement
Advertisement
Trending on CURE
1
Why PSA Monitoring Matters After a Prostate Cancer Diagnosis
2
Rectal Cancer Tumor DNA Fell From 45.8% to 8.7% After Chemotherapy
3
ESMO 2026 Preview: 5 Late-Breaking Trials Patients Should Watch
4
FDA Withdraws Zepzelca Approval for Previously Treated Small Cell Lung Cancer
5